利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

68 条记录 (耗时 0.055 秒)

    Tuberculosis vaccines comprising antigens expressed during the latent infection phase
    41.
    发明授权
    Tuberculosis vaccines comprising antigens expressed during the latent infection phase 有权
    包含在潜伏感染期间表达的抗原的结核病疫苗

    公开(公告)号：US08101193B2

    公开(公告)日：2012-01-24

    申请号：US13101980

    申请日：2011-05-05

    申请人： Claus Aagaard ,  Carina Vingsbo-Lundberg ,  Peter Andersen

    发明人： Claus Aagaard ,  Carina Vingsbo-Lundberg ,  Peter Andersen

    IPC分类号： A61K39/04 ,  A61K39/02 ,  C07H21/04

    CPC分类号： C07K19/00 ,  A61K39/00 ,  A61K39/04 ,  C07K14/35 ,  C07K2319/00

    摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

    摘要翻译： 本发明涉及用于预防，增强或治疗由结核分枝杆菌菌种（M.tuberculosis，M.Bovis，M. africanum，M.Microti）引起的感染的免疫原性组合物，疫苗或药物组合物。 免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。 此外，本发明涉及包含与BCG同时给予的融合多肽序列或本发明的核酸序列的疫苗或与BCG混合或在用于制备所述免疫原性组合物的不同位点或途径单独施用的疫苗的应用， 疫苗或药物组合物。

    VACCINES COMPRISING TB 10.4
    43.
    发明申请
    VACCINES COMPRISING TB 10.4 审中-公开
    包含结核病的疫苗10.4

    公开(公告)号：US20100015171A1

    公开(公告)日：2010-01-21

    申请号：US12500881

    申请日：2009-07-10

    申请人： Jes Dietrich ,  Claus Aagaard ,  Peter Andersen

    发明人： Jes Dietrich ,  Claus Aagaard ,  Peter Andersen

    IPC分类号： A61K39/04 ,  A61K38/16 ,  C07K14/35 ,  A61P37/02

    CPC分类号： A61K39/04 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55561

    摘要： Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-γ, TNF-α, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 μg, as well as 15 μg, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 μg increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.

    摘要翻译： 使用Ag85B-TB10.4和IC31（R）佐剂的组合进行疫苗接种产生大量表达高水平IFN-γ，TNF-α和IL-2的多功能CD4 + T细胞。 这反过来又导致了结核病小鼠气溶胶攻击模型中结核分枝杆菌感染的重大保护。 疫苗的免疫原性及其抗TB感染的能力都高度依赖于抗原剂量。 因此，尽管5杯以及15杯的标准抗原剂量没有诱导对结核分枝杆菌的显着保护，但将剂量降低至0.5杯可将疫苗的免疫原性以及其保护功效提高到可比水平 到BCG接种的小鼠中观察到的。 因此，具有特定抗原剂量的IC31R佐剂可以诱导针对结核分枝杆菌的强烈的保护性Th1应答。

    TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE
    45.
    发明申请
    TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE 有权
    包含在感染相关期间表达的抗原的管炎疫苗

    公开(公告)号：US20090186048A1

    公开(公告)日：2009-07-23

    申请号：US11993199

    申请日：2006-06-20

    申请人： Claus Aagaard ,  Carina Vingsbo-Lundberg ,  Peter Andersen

    发明人： Claus Aagaard ,  Carina Vingsbo-Lundberg ,  Peter Andersen

    IPC分类号： A61K39/04 ,  C07K14/35 ,  A61K38/16 ,  C07H21/00

    CPC分类号： C07K19/00 ,  A61K39/00 ,  A61K39/04 ,  C07K14/35 ,  C07K2319/00

    摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

    摘要翻译： 本发明涉及用于预防，增强或治疗由结核分枝杆菌（M.tuberculosis，M.Bubvis，M. africanum，M.Microti）的种类引起的感染的免疫原性组合物，疫苗或药物组合物。 免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。 此外，本发明涉及包含与BCG同时给予的融合多肽序列或本发明的核酸序列的疫苗或与BCG混合或在用于制备所述免疫原性组合物的不同位点或途径单独施用的疫苗的应用， 疫苗或药物组合物。

    Rotor for an electrical motor
    47.
    发明申请
    Rotor for an electrical motor 失效
    转子用于电机

    公开(公告)号：US20060131980A1

    公开(公告)日：2006-06-22

    申请号：US11311597

    申请日：2005-12-19

    申请人： Niels Weihrauch ,  Peter Andersen

    发明人： Niels Weihrauch ,  Peter Andersen

    IPC分类号： H02K17/16 ,  H02K1/00 ,  H02K19/14 ,  H02K17/42 ,  H02K17/22

    CPC分类号： H02K21/46 ,  H02K1/276

    摘要： The invention provides a rotor for an electrical motor, a tool for making a rotor core and a method of making the rotor. The rotor could be incorporated e.g. in a line-start motor and comprises a squirrel cage and magnet located in a rotor core. The magnets are, in one end of the rotor, secured by an end plate with apertures which are larger than the magnet openings, and the end plate is indexed relative to the magnet slots such that a first portion of openings into the magnet slots is in communication with the aperture and such that a remaining, second, portion of the magnet slots is covered by the end plate. In one aspect, the end plate forms an integrated part of the rotor core and comprises openings cooperating with conductor slots to form through-going passages for conductors of the squirrel cage. In that way, the end plate is held in a completely fixed position by the squirrel cage which is moulded directly onto the core and into the conductor slots.

    摘要翻译： 本发明提供一种用于电动机的转子，用于制造转子芯的工具和制造转子的方法。 转子可以包括在内。 在线路起动电动机中，包括位于转子铁芯中的鼠笼和磁体。 磁体在转子的一端被一个具有大于磁体开口的孔的端板固定，并且端板相对于磁体槽被分度，使得开口进入磁体槽的第一部分位于 与孔的通信，并且使得剩余的第二部分磁体槽被端板覆盖。 在一个方面，端板形成转子芯的集成部分，并且包括与导体槽配合的开口，以形成用于鼠笼的导体的通路。 以这种方式，端板通过直接模制在芯上并进入导体槽的鼠笼保持在完全固定的位置。

    Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
    50.
    发明授权
    Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis 失效
    衍生自结核分枝杆菌的核酸片段和多肽片段

    公开(公告)号：US06641814B1

    公开(公告)日：2003-11-04

    申请号：US09050739

    申请日：1998-03-30

    申请人： Peter Andersen ,  Rikke Nielsen ,  Thomas Oettinger ,  Peter Birk Rasmussen ,  Ida Rosenkrands ,  Karin Weldingh ,  Walter Florio

    发明人： Peter Andersen ,  Rikke Nielsen ,  Thomas Oettinger ,  Peter Birk Rasmussen ,  Ida Rosenkrands ,  Karin Weldingh ,  Walter Florio

    IPC分类号： A61K3902

    CPC分类号： C07K14/35 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/51 ,  C07K2319/00

    摘要： The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

    摘要翻译： 本发明基于许多结核分枝杆菌来源的新蛋白质和蛋白质片段的鉴定和表征（SEQ ID NO：2,4,6,8,10,12,14,16,17-23,42， 48，50，52，54，56，58，60，62，64，66，68，70，72-86，88，90，92，94，141，143，145，147，149，151，153， 和168-171）。 本发明涉及多肽及其免疫活性片段，编码它们的基因，免疫组合物如疫苗和含有多肽的皮肤试验试剂。 本发明的另一部分是基于惊人的发现，即分别与每种未融合的蛋白质相比，ESAT-6和MPT59之间的融合是优越的免疫原。